Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Illumina, Inc. (the "Company"), presented at the J.P. Morgan Healthcare Conference in San Francisco, California during which it discussed preliminary financial results for the fourth quarter and fiscal year ended January 1, 2023. The presentation was webcast on the Company's website, and it will remain available in the Investor Relations section of the Company's website for at least 30 days following. Pursuant to General Instruction F to Form 8-K, a copy of the transcript from the presentation (the "Transcript") is attached hereto as Exhibit 99.1 and is incorporated into this Item 2.02 by this reference.

The information furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

--------------------------------------------------------------------------------

Table of Contents

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Transcript of Illumina, Inc. presentation at the J.P. Morgan Healthcare Conference on January 9, 2023

99.2 Reconciliation of preliminary non-GAAP results of operations for the fiscal year ended January 1, 2023

99.3 Reconciliation of non-GAAP financial guidance for fiscal year 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

Table of Contents

© Edgar Online, source Glimpses